Corcept Therapeutics (CORT)
NASDAQ:CORT
Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$46.16
$0.08(0.16%)
At close: 4:00 PM EST
$46.16
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $91.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.18M
Market Cap
$7.46B
Enterprise Value$7.36B
Total Cash (Recent Filing)$338.18M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)153.6
Beta0.50
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume1,025,346
30 Day Avg. Volume1,180,095
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue9.57
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda-1.08K
Forecast
1Y Price Target
$97.50Price Target Upside111.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.59
Revenue Forecast (FY)$976.58M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet & Cash RunwayExtremely low leverage combined with a $515M cash position provides durable financial flexibility to fund launches, trials and commercialization without near-term refinancing risk. This supports multi-year R&D and commercial scale-up, reducing liquidity-driven disruption to strategic plans.
Very High Gross Margins & Cash GenerationNearly 98% gross margins reflect a highly scalable specialty-pharma model where incremental sales convert strongly to cash. Historically tight cash conversion means the company can reinvest operating cash into pipeline and launches, sustaining growth even as launch spending temporarily rises.
Regulatory Success And Clinically Meaningful Oncology DataAn FDA approval anchored by a pivotal survival benefit materially expands addressable markets and creates a second commercial pillar beyond Cushing's. Durable clinical differentiation accelerates payer and guideline adoption, underpinning multi-year revenue diversification and higher long-term market penetration.
Bears Say
Compressing Profitability And Softer Free Cash FlowMaterial margin compression and weaker FCF reduce internal funding capacity and increase sensitivity to higher launch and commercial spending. If the trend persists, it could pressure investment in trials or force slower expansion, making long-term growth dependent on reestablishing prior profitability levels.
Net Loss And Operational/payer HeadwindsA swing to a near-term net loss driven by launch and support costs, combined with payer reauthorization and specialty pharmacy transition delays, highlights revenue recognition and operational fragility. Sustained execution is required to convert patient starts into recurring revenue and restore margin momentum.
DAZALS Tolerability Risk May Affect Pivotal OutcomesTolerability-driven discontinuations necessitating dose‑titration introduce risk to enrollment, adherence and regulatory review. If not resolved, this can delay pivotal readouts, limit label breadth or reduce real-world effectiveness, undermining a key pipeline opportunity over the coming years.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $91.00 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $7.46B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.19.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.533%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.50 (111.22% Upside)
$97.50 (111.22% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.66%
12-Months-Change
Fundamentals
Return on Equity
7.50%
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$97.50
▲(111.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.89% Insiders
15.13% Mutual Funds
16.28% Other Institutional Investors
36.21% Public Companies and
Individual Investors